# Treg Cells for AGVHD in Non-myeloablative UCB Transplant

> **NCT02118311** · PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** T Regulatory cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT02118311
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Changing study design. Will replace with a different protocol.
- **Last updated:** 2017-12-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118311, "Treg Cells for AGVHD in Non-myeloablative UCB Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02118311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*